Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Regulatory News (ABDN)

Share Price Information for Abrdn (ABDN)

Share Price is delayed by 15 minutes
Get Live Data
238.60    -2.40 (-1.00%)
Bid:
237.20
Ask:
237.60
Spread: 0.40 (0.169%)
Market Cap: £4.27b
ABDN Live PriceLast checked at - London Stock Exchange

Intraday Abrdn Share Chart

Governance Changes

26 Mar 2026 08:00

RNS Number : 1614Y
Aberdeen Group PLC
26 March 2026
 

Aberdeen Group plc

 

Governance Changes

 

Aberdeen Group plc ("Aberdeen" or the "Company") today provides an update on its Chair succession process and consequential interim governance changes.

 

At the Company's 2025 AGM, Sir Douglas Flint announced that he would not stand for re-election at the following year's AGM. In January 2026, the Company confirmed that Sir Douglas would step down as Chair and as a Director of the Company with effect from the conclusion of the Company's Board meeting on 28 April 2026. 

 

The process to select a permanent successor to Sir Douglas as Chair of the Company remains ongoing and the Company will provide further updates on this in due course.

 

In the interim, and until a permanent Chair is appointed, the Company confirms that Jonathan Asquith, Senior Independent Director, will assume the role of Chair of the Company, subject to regulatory approval, and Chair of the Nomination and Governance Committee with effect from the conclusion of the Company's Board meeting on 28 April 2026.

 

During the interim period, Hannah Grove, Non-Executive Director, will assume the role of Chair of the Remuneration Committee. John Devine, Non-Executive Director, will assume the role of Senior Independent Director and rejoin the Nomination and Governance Committee. Jonathan will step down as a member of the Audit and Risk Committee.

 

While performing the role of Chair, Jonathan will receive a fee of £475,000 per annum on a prorated basis in line with the Directors' Remuneration Policy approved by shareholders at the 2023 AGM. Jonathan will receive no additional director fees in relation to his other roles in the Company during the period of his interim appointment.

 

Jonathan Asquith said: "On behalf of the Board, I would like to thank Sir Douglas for his exceptional contribution to the Company since joining the Board in 2018. His chairmanship has played a pivotal role in repositioning Aberdeen for success as a leading UK wealth and investments group. On behalf of my colleagues on the Board, I wish him all the very best for the future.

 

I look forward to continuing to work with Jason and his team to ensure the Company doesn't miss a beat in the execution of its growth strategy."

 

Sir Douglas Flint said: "It has been a huge privilege to serve as Chair of Aberdeen. In what has been quite a journey, I am really proud of what the Board and the executive team with the support of our colleagues have achieved together, including simplifying the Group and sharpening our strategic priorities. Jason is leading a first-rate executive team, with a clear strategy aimed at building the UK's leading wealth and investments group. I would like to thank my Aberdeen colleagues for their commitment and support, and I wish Jonathan, Jason and everyone at Aberdeen continued success."

 

The Financial Conduct Authority has been notified of the appointment of Jonathan Asquith as Chair of the Company and the appointment of Hannah Grove as Chair of the Remuneration Committee. Their respective appointments are subject to receipt of relevant regulatory approvals.

 

This announcement is made pursuant to UKLR 6.4.6R.

 

26 March 2026

 

Enquiries:

 

Media

Duncan Young

 

 

+44 (0) 7920 868 865

 

Group Secretariat

Iain Jones

 

 

+44 (0) 7464 917 797

 

* Calls may be monitored and/or recorded to protect both you and us and help with our training. Call charges will vary.

 

 

END

 

LEI number of Aberdeen Group plc: 0TMBS544NMO7GLCE7H90

 

Notes to Editors

 

For the purposes of section 430(2B) of the Companies Act 2006, Sir Douglas Flint will receive his Chair fee (£475,000 per annum) on a prorated basis until 28 April 2026. He is not entitled to any payments for loss of office.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDXSUDDGLU
Date   Source Headline
26th Mar 202510:55 amRNSForm 8.3 - Assura plc
24th Mar 202512:41 pmRNSForm 8.3 - Assura plc
24th Mar 202512:38 pmRNSForm 8.3 - Primary Health Properties plc
24th Mar 202512:35 pmRNSForm 8.3 - Wood Group (John) plc
21st Mar 202510:40 amRNSForm 8.3 - Primary Health Properties PLC
20th Mar 20252:06 pmRNSHolding(s) in Company
20th Mar 202511:50 amRNSForm 8.3 - Wood Group (John) plc
20th Mar 202511:47 amRNSForm 8.3 - Primary Health Properties PLC
20th Mar 202511:44 amRNSForm 8.3 - Assura plc
18th Mar 20255:37 pmRNSHolding(s) in Company
18th Mar 202511:54 amRNSForm 8.3 - Primary Health Properties PLC
18th Mar 202511:51 amRNSForm 8.3 - Assura plc
17th Mar 20253:46 pmRNSDirector/PDMR Shareholding
17th Mar 202512:01 pmRNSForm 8.3 - Wood Group (John) plc
17th Mar 202511:57 amRNSForm 8.3 - Primary Health Properties PLC
17th Mar 202511:55 amRNSForm 8.3 - Assura plc
14th Mar 20255:20 pmRNSHolding(s) in Company
14th Mar 20252:57 pmRNSHolding(s) in Company
13th Mar 20252:41 pmRNSHolding(s) in Company
13th Mar 202512:25 pmRNSForm 8.3 - Wood Group (John) plc
13th Mar 202512:22 pmRNSForm 8.3 - Primary Health Properties PLC
13th Mar 202512:09 pmRNSForm 8.3 - Assura PLC
13th Mar 20259:40 amRNSChange of Name Effective
12th Mar 20255:34 pmRNSHolding(s) in Company
11th Mar 20252:31 pmRNSForm 8.3 - Primary Health Properties PLC
11th Mar 202512:05 pmRNSForm 8.3 - Wood Group (John) plc
11th Mar 202511:16 amRNSForm 8.3 - Assura plc
10th Mar 202512:25 pmRNSForm 8.3 - Assura plc
6th Mar 20254:08 pmRNSWood Group (John) plc - DUPLICATE
6th Mar 202512:16 pmRNSWood Group (John) plc
6th Mar 202512:08 pmRNSForm 8.3 - Wood Group (John) plc
5th Mar 20259:44 amRNSHolding(s) in Company
4th Mar 20254:00 pmRNSHolding(s) in Company
4th Mar 20257:00 amRNSFinal Results - Part 7 of 7
4th Mar 20257:00 amRNSFinal Results - Part 6 of 7
4th Mar 20257:00 amRNSFinal Results - Part 5 of 7
4th Mar 20257:00 amRNSFinal Results - Part 4 of 7
4th Mar 20257:00 amRNSFinal Results - Part 3 of 7
4th Mar 20257:00 amRNSFinal Results - Part 2 of 7
4th Mar 20257:00 amRNSFinal Results - Part 1 of 7
3rd Mar 20253:05 pmRNSHolding(s) in Company
3rd Mar 202512:21 pmRNSForm 8.3 - Wood Group (John) plc
3rd Mar 20259:59 amRNSTotal Voting Rights
28th Feb 20257:00 amRNSDirectorate Change - Group CFO Appointment
27th Feb 20253:45 pmRNSHolding(s) in Company
25th Feb 20251:26 pmRNSForm 8.3 - Wood Group (John) plc
20th Feb 20259:28 amRNSForm 8.3 - Assura plc
19th Feb 20251:44 pmRNSForm 8.3 - Assura plc
18th Feb 202511:56 amRNSForm 8.3 - Assura plc
17th Feb 20252:31 pmRNSForm 8.3 - Assura plc (OPD)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.